Cancer Immunology Reserch

Cancer Immunol Res. 2025 Apr 16. doi: 10.1158/2326-6066.CIR-24-1050. Online ahead of print. ABSTRACT CAR T-cell therapy has improved outcomes for patients with chemotherapy-resistant B-cell malignancies. However, CAR T-cell treatment of patients with solid cancers has been more difficult, in part because of the heterogeneous expression of tumor-specific cell surface antigens. Here, we describe the generation … Read more

Cancer Immunol Res. 2025 Apr 15:OF1-OF15. doi: 10.1158/2326-6066.CIR-24-0894. Online ahead of print. ABSTRACT T-cell senescence occurs in the tumor microenvironment (TME) and influences cancer outcomes, as well as the effectiveness of immunotherapies. The TME triggers this T-cell senescence via multiple pathways, including persistent stimulation with tumor-associated antigens, altered metabolic pathways, and activation of chronic inflammatory … Read more

Cancer Immunol Res. 2025 Apr 11. doi: 10.1158/2326-6066.CIR-24-0333. Online ahead of print. ABSTRACT The optimal means to prime for effective anti-tumor immunity in a cancer patient remains elusive in the current era of checkpoint blockade. Crafting a strategy to amplify CD8+ T cells while blocking regulatory cells should increase immunotherapy efficacy. Biomaterial carriers have been … Read more

Cancer Immunol Res. 2025 Apr 10. doi: 10.1158/2326-6066.CIR-24-0807. Online ahead of print. ABSTRACT The lack of response of glioblastoma (GBM) to immunotherapy is closely related to the limited number of T cells in the tumor microenvironment (TME). However, it is still not known why GBM is characterized by an immune-cold TME with reduced CD8+ T-cell … Read more

Cancer Immunol Res. 2025 Apr 2;13(4):453. doi: 10.1158/2326-6066.CIR-13-4-WWR. NO ABSTRACT PMID:40170562 | DOI:10.1158/2326-6066.CIR-13-4-WWR

Cancer Immunol Res. 2025 Apr 1. doi: 10.1158/2326-6066.CIR-24-0746. Online ahead of print. ABSTRACT Philadelphia-like acute lymphoblastic leukemia (Ph-like ALL) is a molecularly distinct tyrosine kinase-driven cancer that has a high relapse rate and poor response toward combinatorial chemotherapy. Tyrosine kinase inhibitors (TKI) in the clinic improve the survival of patients with Ph-like ALL. Engineered antibody … Read more

Cancer Immunol Res. 2025 Apr 1. doi: 10.1158/2326-6066.CIR-24-0834. Online ahead of print. ABSTRACT Local immunotherapy stimulates immune responses against tumors while avoiding adverse effects associated with systemic administration. However, current strategies for tumor-targeted in situ immunotherapy are still limited. mRNA-based gene therapy represents a promising strategy. Gasdermin E (GSDME)-mediated pyroptosis is reported to exert anti-tumor … Read more

Cancer Immunol Res. 2025 Apr 1. doi: 10.1158/2326-6066.CIR-24-0598. Online ahead of print. ABSTRACT Memory-phenotype (MP) CD4+ T lymphocytes spontaneously develop in steady state from peripheral naïve precursors in a manner dependent on self-antigen recognition. While MP cells possess innate type 1 and 3 effector functions that can contribute to host defense and autoimmunity, their immunological … Read more

Cancer Immunol Res. 2025 Mar 27. doi: 10.1158/2326-6066.CIR-24-0737. Online ahead of print. ABSTRACT Immunosuppressive myeloid cells are critical obstacles to T cell-centered immune checkpoint blockade therapies, which have been successful in treating a fraction of cancer patients. How tumor cells interact with myeloid cells to regulate immune responses and tumor development is unclear. Here, we … Read more

Cancer Immunol Res. 2025 Mar 27. doi: 10.1158/2326-6066.CIR-24-1055. Online ahead of print. ABSTRACT The systemic immunological effects of combining anti-CTLA4 therapy with PD-(L)1 blockade remain incompletely characterized, despite the widespread use of this combination in treating various solid tumors across multiple stages of disease. Herein, we investigated the additive impact of anti-CTLA4 on peripheral immune … Read more